Axxicon wants to acquire new funding of up to € 1.5 million to accelerate growth in the microfluidics market. To this end, it issues obligations with a duration of five years at an interest rate of 8.0% through the NPEX stock exchange.
The corona crisis has caused a slowdown in the growth acceleration. During the lockdown, visits to general practitioners and outpatient clinics decreased. This resulted in a decrease of the number of rapid diagnostics tests performed with Axxicon’s products. With the capital to be raised, Axxicon wants to scale up its research, production and sales organization in order to accelerate growth. With this growth capital Axxicon can further expand as a leading microfluidics manufacturer.